In The News

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease

August 17, 2015. This placebo-controlled, double-blind, parallel group, randomized trial compared 24 patients with type 2 diabetes (T2D) and end-stage renal disease (ESRD) with 23 control patients with T2D and normal kidney function. Patients were randomly allocated on a 1:1 basis to 12 weeks of subcutaneously injected liraglutide (titrated to 1.8 mg) or placebo. The primary outcome was dose-corrected plasma trough liraglutide concentrations.

Consumption of Sugar-Sweetened Beverages, Artificially Sweetened Beverages, and Fruit Juice and Incidence of Type 2 Diabetes: Systematic Review, Meta-Analysis, and Estimation of Population Attributable Fraction

July 21, 2015. This systematic review and random effects meta-analysis examined the association between the consumption by patients with type 2 diabetes (T2D) of: a) sugar-sweetened beverages; b) artificially sweetened beverages; and c) fruit juice. Data were adjusted for adiposity. Before adjustment, the daily consumption of a single serving of a sugar-sweetened beverage was associated with an 18% increased incidence of T2D (95% confidence interval [CI]: 9% to 28%). After adjustment, this risk was 13% (95% CI 6% to 21%).

An Observational Study of Patient Characteristics and Mortality Following Hypoglycemia in the Community

June 30, 2015. In this prospective, observational study, data from emergency services calls for hypoglycemia were recorded. The study ran from 2005 to 2013 in an area covering 34,000 patients with diabetes. Variables analyzed included capillary blood glucose (BG), A1C levels, treatment administered for hypoglycemia, as well as subsequent 12-month mortality rates and factors predicting survival. Participants (n=1156) experienced 1835 episodes; 45% had type 1 diabetes (T1D) and 44% had type 2 diabetes (T2D); the remainder were not classified by diabetes type.

Meal Memory—A Useful, Low-Hassle Diabetes App

July 27, 2015. This week’s issue of diaTribe gives a thumbs-up to a new diabetes app called Meal Memory, available free for Apple and Android. Here’s how it works: users take a picture of every meal; their associated pre/post-meal blood glucose measures are paired with the meal to provide a clear visualization of how each meal impacts blood glucose. Patients who use Dexcom Share or Apple Health systems can automatically upload their glucose data to Meal Memory; patients using other meters may need to manually import their data.

FDA Proposes Additional Revisions to the Nutrition Facts Label

July 27, 2014. The US Food and Drug Administration (FDA) is proposing additional revisions to the Nutrition Facts label for packaged foods. This proposal would require declaration of the percent daily value (%DV) for added sugars, among other changes. The FDA is seeking public comment on the proposal for 75 days.

Efficacy and Safety of Liraglutide vs Placebo Added to Basal Insulin Analogues (With or Without Metformin) in Patients With Type 2 Diabetes: A Randomized, Placebo-Controlled Trial

This 26-week, double-blind, parallel-group trial was conducted to confirm the superiority of adding liraglutide vs placebo to preexisting treatment with basal insulin plus metformin in patients with inadequately controlled type 2 diabetes (T2D). Patients (N=451) were randomized to liraglutide 1.8 mg once daily (with dose escalation over 2 weeks) or placebo. The primary endpoint was A1C reductions; post-randomization increases to patient insulin doses were not allowed. At 26 weeks, A1C levels were lower with liraglutide (-1.3%) than placebo (-0.1%; P<0.0001).

Glycemic Control and Hypoglycemia With New Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Patients With Type 2 Diabetes Using Basal Insulin and Oral Antihyperglycemic Drugs

This randomized, multicenter, open-label, two-arm study compared the efficacy of insulin glargine 300 U/mL (Gla-300) vs 100 U/mL (Gla-100) in patients with type 2 diabetes treated with basal insulin and oral antihyperglycemic drugs (excluding sulfonylureas). The study (EDITION 2) was conducted over 12 months. Both Gla-300 and Gla-100 were associated with A1C reductions from baseline (-0.55% vs -0.50%, respectively).

Combination of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin With Insulin-Based Regimens in Type 2 Diabetes and Chronic Kidney Disease

Since limited glucose-lowering treatment options are available for type 2 diabetes (T2D) patients with chronic kidney disease (CKD), this study evaluated the safety and efficacy of linagliptin plus insulin in patients with T2D and mild-to-severe renal impairment. Participant data were obtained from 2 phase 3 trials (N=811). After 24 weeks, mean placebo-adjusted A1C reductions from baseline of −0.59% were observed in patients with mild renal impairment and −0.69% in patients with moderate renal impairment.

A Randomized, Controlled Trial of Liraglutide 3.0 mg in Weight Management

This 56-week, double-blind trial included 3731 patients with a body mass index (BMI) of at least 30 kg/m2 (or 27 kg/m2 in individuals with treated or untreated dyslipidemia or hypertension) who did not have type 2 diabetes. Patients were randomly assigned in a 2:1 ratio to receive lifestyle modification counseling plus a once-daily injection of liraglutide 3.0 mg or placebo. The primary endpoints were change in body weight and the proportion of patients losing at least 5% and more than 10% of their initial body weight.

An Observational Study of Patient Characteristics and Mortality Following Hypoglycemia in the Community

This study identified patient characteristics and mortality rates associated with severe hypoglycemic events requiring emergency services intervention. Data (2005-2013) were obtained as part of emergency services calls for hypoglycemia treatment in a UK community with 34,000 residents with diabetes. Investigators identified 1835 hypoglycemic events among 1156 patients, 44% with type 2 diabetes (T2D) and 45% with type 1 diabetes (T1D). Investigators found that patients with severe hypoglycemia and T1D were more likely to be male.